CareDx, Inc. - Common Stock (CDNA)

The diagnostics leader is accelerating the trend toward precision medicine.

CareDx (NASDAQ:CDNA) reported second-quarter 2026 revenue growth of 52% as the transplant diagnostics company expanded testing services, completed the sale of its lab products business and began integrating the recently acquired NavDx specialty oncology platform. Total revenue rose to $132 million

CareDx, a leader in transplant diagnostics, saw a key insider reduce his direct holdings amid a series of scheduled transactions.

CareDx (NASDAQ:CDNA) executives outlined the company’s strategy to focus on precision diagnostics, expand into minimal residual disease testing and improve profitability during a Goldman Sachs-hosted discussion. Chief Executive Officer John Hanna said CareDx has reshaped its portfolio around areas

CareDx (NASDAQ:CDNA) executives outlined the company’s growth strategy, first-quarter performance and pipeline priorities during a presentation at the Jefferies Healthcare Conference, emphasizing transplant diagnostics, specialty oncology and digital workflow integration. John Hanna, chief executiv

CareDx (CDNA) Q1 2026 Earnings Call Transcript

CareDx (CDNA) Q2 2025 Earnings Transcript

CareDx (CDNA) Q4 2025 Earnings Call Transcript

Power Solutions International designs and manufactures advanced engines and power systems for industrial and transportation markets.

This SaaS firm delivers cloud-based business software worldwide, focusing on subscription-driven customer and IT service solutions.

Air Lease Corporation provides global airlines with commercial jet leasing, sales, and fleet management services across a diverse portfolio.

Five9 delivers cloud-based contact center software for enterprises, serving clients across finance, healthcare, and technology sectors.

Freshworks delivers cloud-based SaaS solutions for customer engagement, IT service management, and business process automation.